EPO and chronic kidney disease: As with patient studies of EPO administration in chronic kidney disease and stroke [195,196,211], comorbidities and concomitant treatments such as a clot-busting (thrombolytic) drug for reperfusion therapy are also likely to influence responses to EPO treatment in myocardial infarction.